Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) revealed earnings for its first quarter that Increased, from last year
The company's bottom line totaled RMB298.71 million, or RMB0.93 per share. This compares with RMB269.28 million, or RMB0.84 per share, last year.
The company's revenue for the period rose 1.6% to RMB723.55 million from RMB712.11 million last year.
Tibet Rhodiola Pharmaceutical Holding Co. earnings at a glance (GAAP) :
-Earnings: RMB298.71 Mln. vs. RMB269.28 Mln. last year.-EPS: RMB0.93 vs. RMB0.84 last year.-Revenue: RMB723.55 Mln vs. RMB712.11 Mln last year.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.